Carsten Krieg

Carsten Krieg

Auto-generated profile, based on publicly available information

Carsten Krieg

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CKCarsten Krieg
Carsten Krieg
MNMalgorzata Nowicka
Malgorzata Nowicka
SGSilvia Guglietta
Silvia Guglietta
SSSabrina Schindler
Sabrina Schindler
FHFelix J Hartmann
Felix J Hartmann
BBBurkhard Becher
Burkhard Becher

25 March 2012 in Nature
Verified
Journal Article
Open access
PDF file
ALAron M. Levin
Aron M. Levin
DBDarren L. Bates
Darren L. Bates
ARAaron M. Ring
Aaron M. Ring
CKCarsten Krieg
Carsten Krieg
JLJack T. Lin
Jack T. Lin
KGK. Christopher Garcia
K. Christopher Garcia
Although IL-2 has been studied for its immune-stimulating activity against metastatic cancer, its side effects have limited its clinical use; here, an engineered IL-2 ‘superkine’ is shown to have increased activity, particularly in inducing antitumour T cells, but fewer side effects. Chris Garcia and colleagues elucidate the molecular mechanism that underlies the sensitization of T cells to the immunostimulatory cytokine interleukin-2 (IL-2). They use this information to engineer a single-chain IL-2 superkine that functions independent of its α-receptor (IL-2Rα or CD25). This new superkine is more efficacious than IL-2 in inducing antitumour T-cell responses and has fewer toxic side effects. The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of leukocytes, including T cells and natural killer (NK) cells1,2,3. Considerable effort has been invested in using IL-2 as a therapeutic agent for a variety of immune disorders ranging from AIDS to cancer. However, adverse effects have limited its use in the clinic. On activated T cells, IL-2 signals through a quaternary ‘high affinity’ receptor complex consisting of IL-2, IL-2Rα (termed CD25), IL-2Rβ and IL-2Rγ4,5,6,7,8. Naive T cells express only a low density of IL-2Rβ and IL-2Rγ, and are therefore relatively insensitive to IL-2, but acquire sensitivity after CD25 expression, which captures the cytokine and presents it to IL-2Rβ and IL-2Rγ. Here, using in vitro evolution, we eliminated the functional requirement of IL-2 for CD25 expression by engineering an IL-2 ‘superkine’ (also called super-2) with increased binding affinity for IL-2Rβ. Crystal structures of the IL-2 superkine in free and receptor-bound forms showed that the evolved mutations are principally in the core of the cytokine, and molecular dynamics simulations indicated that the evolved mutations stabilized IL-2, reducing the flexibility of a helix in the IL-2Rβ binding site, into an optimized receptor-binding conformation resembling that when bound to CD25. The evolved mutations in the IL-2 superkine recapitulated the functional role of CD25 by eliciting potent phosphorylation of STAT5 and vigorous proliferation of T cells irrespective of CD25 expression. Compared to IL-2, the IL-2 superkine induced superior expansion of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionally less expansion of T regulatory cells and reduced pulmonary oedema. Collectively, we show that in vitro evolution has mimicked the functional role of CD25 in enhancing IL-2 potency and regulating target cell specificity, which has implications for immunotherapy.

1 May 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
JWJohn M Wrangle
John M Wrangle
VVVamsidhar Velcheti
Vamsidhar Velcheti
MPManish R Patel
Manish R Patel
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
EHElizabeth G Hill
Elizabeth G Hill
MRMark P Rubinstein
Mark P Rubinstein

14 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CKCarsten Krieg
Carsten Krieg
SLSven Létourneau
Sven Létourneau
GPGiuseppe Pantaleo
Giuseppe Pantaleo
OBOnur Boyman
Onur Boyman
IL-2 immunotherapy is an attractive treatment option for certain metastatic cancers. However, administration of IL-2 to patients can lead, by ill-defined mechanisms, to toxic adverse effects including severe pulmonary edema. Here, we show that IL-2–induced pulmonary edema is caused by direct interaction of IL-2 with functional IL-2 receptors (IL-2R) on lung endothelial cells in vivo. Treatment of mice with high-dose IL-2 led to efficient expansion of effector immune cells expressing high levels of IL-2Rβγ, including CD8+T cells and natural killer cells, which resulted in a considerable antitumor response against s.c. and pulmonary B16 melanoma nodules. However, high-dose IL-2 treatment also affected immune cell lineage marker-negative CD31+pulmonary endothelial cells via binding to functional αβγ IL-2Rs, expressed at low to intermediate levels on these cells, thus causing pulmonary edema. Notably, IL-2–mediated pulmonary edema was abrogated by a blocking antibody to IL-2Rα (CD25), genetic disruption of CD25, or the use of IL-2Rβγ–directed IL-2/anti-IL-2 antibody complexes, thereby interfering with IL-2 binding to IL-2Rαβγ+pulmonary endothelial cells. Moreover, IL-2/anti-IL-2 antibody complexes led to vigorous activation of IL-2Rβγ+effector immune cells, which generated a dramatic antitumor response. Thus, IL-2/anti-IL-2 antibody complexes might improve current strategies of IL-2–based tumor immunotherapy.

26 May 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
MNMalgorzata Nowicka
Malgorzata Nowicka
CKCarsten Krieg
Carsten Krieg
LWLukas M. Weber
Lukas M. Weber
FHFelix J. Hartmann
Felix J. Hartmann
SGSilvia Guglietta
Silvia Guglietta
MRMark D. Robinson
Mark D. Robinson
High dimensional mass and flow cytometry (HDCyto) experiments have become a method of choice for high throughput interrogation and characterization of cell populations.Here, we present an R-based pipeline for differential analyses of HDCyto data, largely based on Bioconductor packages. We computationally define cell populations using FlowSOM clustering, and facilitate an optional but reproducible strategy for manual merging of algorithm-generated clusters. Our workflow offers different analysis paths, including association of cell type abundance with a phenotype or changes in signaling markers within specific subpopulations, or differential analyses of aggregated signals. Importantly, the differential analyses we show are based on regression frameworks where the HDCyto data is the response; thus, we are able to model arbitrary experimental designs, such as those with batch effects, paired designs and so on. In particular, we apply generalized linear mixed models to analyses of cell population abundance or cell-population-specific analyses of signaling markers, allowing overdispersion in cell count or aggregated signals across samples to be appropriately modeled. To support the formal statistical analyses, we encourage exploratory data analysis at every step, including quality control (e.g. multi-dimensional scaling plots), reporting of clustering results (dimensionality reduction, heatmaps with dendrograms) and differential analyses (e.g. plots of aggregated signals).

30 November 2015 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FMFlorian Mair
Florian Mair
FHFelix J. Hartmann
Felix J. Hartmann
DMDunja Mrdjen
Dunja Mrdjen
VTVinko Tosevski
Vinko Tosevski
CKCarsten Krieg
Carsten Krieg
BBBurkhard Becher
Burkhard Becher